Over the past decade Prosurgics has developed a significant technological base in surgical robotics technology, and in recent years has achieved leadership in “image-guided” surgical robots – combining the accuracy of robotics with the power and resolution of modern medical imaging (MRI and CT). 
The company has built a focused platform of intellectual property and international regulatory approval for its first two products.  Over the past 18 months, a new management team has transitioned Prosurgics from it’s predominant R&D focus to become a commercially driven and outwardly facing organisation, meeting the needs of its growing customer base.

The surgical robotics market is evolving rapidly, with global revenues of $200m in 2005 expected to rise to $1-2bn in the medium term. Prosurgics’s robots do not replace the surgeon, but rather empower skilled surgeons to achieve even better results. The benefits of surgical robotics include improved patient outcomes, reduced hospitalisation and recovery times, reduced surgeon fatigue; and can also offer a positive financial impact to healthcare providers.

The groundbreaking PathFinder robot for neurosurgery is a product which has the potential to redefine the standard of care in important areas of neurosurgery. Results during the treatment of serious disorders such as epilepsy and Parkinson’s disease suggest that PathFinder will become an enabling technology, its unrivalled accuracy allowing the development of new surgical approaches, and extending the possibility of treatment to more patients.

In tune with the way healthcare is evolving internationally, Prosurgics is applying its technology to develop products that will maximise efficiency in service delivery. The company’s robotic camera holder provides an “additional hand” for surgeons performing keyhole surgery, shortening operations and reducing staffing needs. The company’s vision is to make this type of product ubiquitous in keyhole surgery. To achieve this ambitious target the company is redefining the accepted capital sales model for such products to a hybrid of lower capital cost combined with highly efficient single-use-product revenue streams. This departure shifts the company from reliance on resource-intensive and lengthy capital goods selling processes, aligning it with best commercial practice in the medical device industry.

At the heart of Prosurgics’s progress over the past year has been the development of a keen understanding of the evolving needs of its customers, both existing and potential, to signal and reflect the company’s re-emphasised customer orientation and commercial focus. The business has been renamed and completely rebranded from the original name Armstrong to reflect the new focus of the business